Pure Financial Advisors LLC Lowers Holdings in IQVIA Holdings Inc. $IQV

Pure Financial Advisors LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.3% in the third quarter, Holdings Channel reports. The firm owned 10,939 shares of the medical research company’s stock after selling 2,618 shares during the period. Pure Financial Advisors LLC’s holdings in IQVIA were worth $2,078,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Asset Dedication LLC boosted its stake in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after buying an additional 168 shares during the period. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA during the 2nd quarter valued at about $39,000. J.Safra Asset Management Corp grew its holdings in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares in the last quarter. Rothschild Investment LLC increased its position in shares of IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC raised its stake in IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 189 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IQV shares. Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. JPMorgan Chase & Co. increased their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Morgan Stanley upped their price objective on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Finally, HSBC raised IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $243.19.

IQVIA Stock Up 0.3%

Shares of NYSE:IQV opened at $227.74 on Wednesday. The stock has a market capitalization of $38.78 billion, a P/E ratio of 31.24, a price-to-earnings-growth ratio of 2.51 and a beta of 1.37. The stock’s 50-day moving average price is $221.65 and its 200-day moving average price is $196.33. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $234.29.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.